Laboratory Products
Utilising CDX Mouse Models for Preclinical Studies in AML Research
Mar 27 2023
TransCure bioServices has created cell line-derived xenograft (CDX) mouse models which will change the approach of researchers towards preclinical studies of cancer therapies for acute myeloid leukaemia (AML). With these models, researchers can obtain in-depth understanding of the efficacy and toxicity of AML treatments, ultimately resulting in the development of superior therapies and bringing optimism to the numerous patients diagnosed with AML annually.
Acute myeloid leukemia (AML) originates in the bone marrow and rapidly spreads throughout the bloodstream, affecting white and red blood cells as well as platelets. Standard mouse models are commonly used in preclinical studies to investigate AML therapies, but they cannot replicate human immune responses to the disease, which significantly influences its progression. Therefore, these models lack human-relevant efficacy when it comes to clinical trials. Moreover, due to the fast progression and acute nature of AML, inadequate mouse models struggle to accurately reflect its development. Furthermore, cancer cells spreading throughout the body pose challenges for monitoring preclinical treatment efficacy.
The latest mouse model for AML involves injecting AML luciferase tumour cell lines into mice, which permits the tracking of disease progression via bioluminescence imaging. By employing this model, researchers can now more effectively observe the in vivo behaviour of their AML therapies, while also acquiring a comprehensive understanding of the functional characterisation of AML pathogenesis.
More information online
Digital Edition
ILM 49.5 July
July 2024
Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...
View all digital editions
Events
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Aug 25 2024 Copenhagen, Denmark